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Autologous Bone Marrow Transplantation for Patients With Myelodysplastic 
Syndrome (MDS) or Acute Myeloid Leukemia Following MDS
By Theo De Witte, Anja Van Biezen, Jo Hermans, Myrïam Labopin, Volker Runde, Reuven Or, Giovanna Meloni, 
Salut Brunet Mauri, Angelo Carella, Jane Apperley, Alois Gratwohl, and Jean-Pierre Laporte for the Chronic and 
Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation
Intensive chemotherapy followed by autologous bone mar­
row transplantation (ABMT) may provide an alternative ther­
apy for young patients with myelodysplastic syndrome 
(MDS) or acute myeloid leukemia following MDS (sAML) 
lacking a suitable donor. We report the results for 79 patients 
with MDS/sAML transplanted with autologous marrow in 
first complete remission (CR). Within the total group of 79, 
a cohort of 55 patients for whom the duration of first OR 
was known were compared with a matched control group 
of 110 patients with de novo AML. The 2-year survival, dis­
ease-free survival (DFS), and relapse rates for the 79 patients 
transplanted in first CR were 39%, 34%, and 64%, respec­
tively. The relapse risk was greater than 55% for all stages 
and all disease categories. Patients younger than 40 years 
had a significantly (P — .04) better DFS (39%) than patients
older than 40 years (25%). The DFS at 2 years was 28% for 
the cohort of 55 patients transplanted for MDS/sAML and 
51% for those transplanted for de novo AML (P = .025). Re­
lapse rates were 69% for patients with MDS/sAML and 40% 
for those with de novo AML (P = .007). ABMT for MDS or 
secondary leukemia results in a lower DFS when compared 
with similarly treated patients with de novo AML due to a 
higher relapse rate. The DFS of 28% for these patients sug­
gests that autotransplantation may be a valuable therapy 
for this disease. The low treatment-related mortality rate of 
less than 10% supports the view that sufficient numbers of 
hematopoietic stem cells are present in patients with MDS 
to allow adequate repopulation after autologous stem-cell 
transplantation.
© 1997 by The American Society of Hematology.
HE MYELODYSPLASTIC syndromes (MDSs) are a 
heterogeneous group o f disorders with a variable prog­
nosis. The outlook of patients with refractory anemia with 
excess of blasts (RAEB), refractory anemia with excess of 
blasts in transformation (RAEBt), therapy-related MDS, or 
secondary acute myeloblastic leukemia (sAML; secondary 
leukemia) is poor, with median survival times of less than 
12 months.1,2 If patients with these disorders are treated with 
intensive chemotherapy, approximately 50% to 60% will 
achieve complete remission (CR), but the median remission 
duration is less than 8 months despite maintenance chemo-
Young patients can be treated successfully byîrapy
allogeneic bone marrow transplantation (BMT), if a histo- 
compatible sibling donor is available.4'7 Intensive chemo­
therapy followed by autologous BMT (ABMT) may provide 
an alternative therapy for patients who lack a suitable donor. 
To date, ABMT has been reported for a small number of 
patients.8"11
The Chronic Leukemia Registry of the European Group 
for Blood and Marrow Transplantation contained 114 reports 
o f  patients autografted for MDS or secondary leukemia. We 
wished to use this data to determine the feasibility of ABMT 
in these patients by assessing overall survival, disease-free 
survival (DFS), transplant-related mortality, and relapse risk 
for patients treated by ABMT as consolidation treatment in 
first CR. In addition, we studied the effect of various prog­
nostic factors, eg, stage and nature of disease and age of 
patient, on outcome of transplant.
In a second analysis, we wished to compare the outcomes 
o f  ABMT for MDS and secondary leukemia with that seen 
in patients who receive autologous transplants for de novo 
AML. The interval between attainment of CR and transplant 
may differ in these two groups of patients, with the physician 
less likely to proceed to early transplant in patients with 
M DS. The interval between first CR and BMT is known to 
be a prognostic factor in AML,1- but this information was 
not available for all patients reported to the registry. We 
therefore restricted this analysis to the 55 patients for whom 
this information was provided, and compared their outcome
with that of 110 patients transplanted in first CR for de novo 
AML.
MATERIALS AND METHODS
Data were retrieved from the registries of the Chronic and Acute 
Leukemia Working Parties of the European Group for Blood and 
Marrow Transplantation. These registries continuously collect data 
related to patients transplanted by member teams. Reports were 
available for 114 patients from 41 centers. Seventy-nine of these 
patients were transplanted in first CR: 19 for RAEB or RAEBt, 39 
for secondary leukemia, and 2 1 for MDS or secondary leukemia due 
to previous cytotoxic therapy. The median age for the 79 patients 
was 39 years (range, 0 to 63). Forty-five of 79 patients were aged 
less than 40 at the time of transplant (Table 1). The median interval 
between diagnosis and BMT was 9 months (range, 2 to 42) for 
19 patients with MDS and 7 months (range, 3 to 23) for patients
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Table 1. Patients With MDS, sAML, or Therapy-Related MDS/
Leukemia Treated With ABMT in First CR
Patients transplanted in first CR 79
Disease category
MDS 19
sAML 39
Therapy-related MDS/leukemia 21
Age (yr)
<40 45
5:40 34
Status
?
Alive 36
Relapse-free alive 32
Relapse 40
Dead 43
Treatment-related death 7
40%, 30%, and 36%, respectively. The relapse rates for these 
groups are 58%, 68%, and 60%, respectively. The treatment- 
related mortality rate in all three groups was less than 10% 
(Table 2). The overall survival, DFS, and relapse risk were 
not statistically significant different among these three 
groups of patients (Table 2). In contrast, the DFS of patients 
treated below the age of 40 years was significantly (P =  
.04) better (39%) than that for older patients (25%). This 
difference was mainly due to a significantly higher relapse 
rate (72%) in patients transplanted over the age 40 years
■05).
transplanted for sAML or therapy-related MDS/AML. Cytogenetic 
data were only available for 18 patients. Seventy-three patients re­
ceived bone marrow only, three patients were treated with collected 
peripheral stem cells, and three patients received both. None of the 
stem-cell grafts was subjected to purging procedures.
For the matched case-control analysis, we selected 55 patients 
with MDS or secondary leukemia for whom information was avail­
able on the interval from CR to transplant, and compared them with 
110 patients treated by ABMT in first CR for de novo AML, and 
reported to the Acute Leukemia Working Party Registry. This regis­
try contains data on approximately 1,000 patients treated in this way. 
Patients were matched for age (<40 v &40 years), interval from 
first CR (±1 month), and year of transplant.
Definitions, The classification of MDS and AML was performed 
according to the criteria of the French-American-British (FAB) 
working group.13 AML that develops after antecedent MDS with a 
duration of at least 3 months is defined as sAML (secondary leuke-
than in younger patients (59%, P
Matched case-control study. Fifty-five patients trans­
planted in first CR of MDS/sAML were compared with 110 
patients transplanted in first CR of de novo AML. Patients 
were matched for age, year of transplant, and interval from 
CR to transplant (Table 3). Eighteen patients are disease- 
free survivors following treatment for MDS/sAML and 58 
patients survive without leukemia relapse after transplant for 
de novo AML.
The survival at 2 years after ABMT was 31% for 55 
patients with MDS/sAML and 54% for 110 patients with 
de novo AML (P = .005). The DFS was 28% and 51%, 
respectively (P =  .025). The relapse rate was 69% for pa­
tients treated for MDS or secondary leukemia, and 40% for 
those transplanted for de novo AML (P  = .007; Fig 1A 
through C). The treatment-related mortality rate was 9% for 
55 patients transplanted for MDS/sAML and 14% for 110
patients transplanted for de novo AML (P .99).
DISCUSSION
Allogeneic BMT is the treatment of choice in the majority 
of young patients with MDS or secondary leukemias. The 
results are gratifying, but the majority of patients lack a
mia). MDS or AML occurring after chemotherapy or radiotherapy su itab le  donor.4'8 Patients w ith  poor risk features who are 
is defined as therapy-related MDS or AML. b e low  the age o f  65 years m ay be cand idates  for treatment
CR is defined as a normocellular marrow with less than 5% blast 
cells, including monocytoid cells, and less than 10% blast cells and 
promyelocytes. Peripheral blood counts should be in the normal 
range.
Statistics. The intervals for survival, DFS, relapse rate, and risk 
of transplant-related mortality were calculated from BMT. Relapsed 
patients were censored for transplant-related mortality from time of 
relapse. The prognostic value of covariables was studied by Kaplan- 
Meier curves and the log-rank test. The matched control study was 
analyzed with the stratified log-rank test.
RESULTS
Seventy-nine patients transplanted in first CR were assess­
able (Table 1). Thirty-two patients (41%) are alive and dis­
ease-free. The median follow-up duration of 36 surviving 
patients was 10 months (range, 0 to 89 months) and 12 
months (range, 0 to 89) for patients remaining in CR. Only 
seven patients died as a consequence of treatment and 36 
after disease recurrence. Forty patients relapsed (51%). Fif­
teen patients are disease-free survivors more than 2 years 
after transplant. At 2 years post-ABMT, the overall survival, 
DFS, and relapse rates were 39%, 34%, and 64%, respec­
tively.
The 2-year DFS rates for patients transplanted with MDS, 
secondary leukemia, and therapy-related MDS/sAML were
with combination chemotherapy.
Chemotherapy, such as that applied to induce CR in de 
novo AML, showed CR rates varying from 15% to 64%.1'3'l4,l,‘i 
The overall CR rates of patients with MDS or secondary 
leukemia are usually lower than those of patients with de 
novo AML treated with similar chemotherapy regimens. 
However, patients with RAEB, RAEBt, and de novo AML 
showed no difference in treatment outcome when matched 
for prognostic factors such as a history of cytopenias and 
cytogenetics.I(’"IK This may reflect a conflict in defining the 
distinction between MDS and de novo AML. A patient with 
the morphologic picture of RAEBt, but without cytogenetic 
abnormalities and a short history of cytopenias, may respond 
to intensive antileukemic therapy as an average patient with 
de novo AML. On the other hand, a patient with de novo 
AML, trilineage dysplasia, and a monosomy-7 may respond 
as an average patient with MDS or even worse.
Maintaining remission after remission-induction chemo­
therapy is a difficult issue. Patients who are not eligible for 
allogeneic BMT could be treated with postremission chemo­
therapy. Some patients may achieve prolonged DFS|l),2l) with 
this approach, but the overall median remission duration was 
usually less than 12 months.3,21'22 Patients without cytoge­
netic abnormalities appeared to have a better outcome after
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Table 2. Actuarial 2-Year Survival, DFS, Relapse Rate, and Transplant-Related Mortality of 79 Patients Transplanted in First CR With ABMT
Disease category 
MDS 
sAML
Postcytotoxic MDS or sAML
Age (yr)
<40 
a  40
N
19
39
21
45
34
Survival
46%
34%
41%
46%
27%
A b b re v ia tio n : TRM, treatment-related mortality. 
* p value, log-rank test.
.68*
.09
DFS
40%
30%
36%
39%
25%
.61*
.04*
Relapse
58%
68%
60%
59%
72%
.60*
.05*
TRM
5%
5%
10%
.77*
5%
9%
.46*
antileukemic chemotherapy compared with patients with cy­
togenetic abnormalities.1
The experience with ABMT in patients with MDS or leu­
kemia secondary to MDS is limited and the literature con­
tains only case reports.8,9 From a large series of 82 adult 
patients with AML, six patients with a known preceding 
myelodysplastic state received ABMT in first remission. 
Three patients relapsed after transplant, and the overall leu­
kemia-free survival was worse than that of the group without 
an antecedent hematologic disorder.11 A preliminary analysis 
from the European Group for Blood and Marrow Trans­
plantation reported the results of ABMT in 17 patients with 
MDS. Engraftment occurred in 15 of 16 assessable patients. 
The median relapse-free survival duration was 11 months.10 
Transplant-related mortality and death due to regeneration 
failure did not appear to occur more often than after ABMT 
for de novo AML. Hematopoietic engraftment was slow de­
spite the sufficient number of colony-forming units-granulo- 
cyte, macrophage (CFU-GM) being collected per kilogram 
body weight (5 X 104 kg).1H Laporte et al" reported the 
results of ABMT with mafosfamide-treated marrow in pa­
tients with AML following MDS. The hematopoietic en-
Table 3. Comparison of MDS/sAML Study Group With Matched
Control Group of Patients With De Novo AML
Study Group Control Group
No. of patients 55 110
Age (yr)
<40 28 56
^40 27 54
Sex
Male 23 52
Female 32 58
Year of transplant
83-87 8 16
88-90 20 40
91-94 27 54
Interval, first CR to transplantation (mo)
Median 4 4
Range 0-20 0-13
Alive (%) 20 (36) 63 (57)
Relapse-free alive (%> 18 (33) 58 (53)
Relapse (%) 31 (56) 37 (34)
Dead (%) 35 (64) 47 (43)
Treatment-related death (%) 6 (11) 15 (14)
SURVIVALS) A
100
LFS (%) B
75
50
25
■H-----K+ T“L
■I—K 1
0
100
RELAPSE RISK (%) C
MONTHS
p * 0.025
AML
■H-...H ■hr
MDS
Fig 1. (A) Actuarial survival, (B) leukemia-free survival (LFS), and 
(C) relapse risk of 55 patients transplanted in first CR for MDS, sAML, 
or therapy-related MDS/leukemia compared with 110 matched pa­
tients transplanted in first CR for de novo AML. MDS refers to myelo- 
dyspfastic syndromes, secondary AML, and therapy related MDS/ 
AML; AML refers to de novo AML.
1
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graftment was also slow in these seven patients, but all pa­
tients engrafted except for one who died of treatment-related 
causes before engrafting.
MDSs are clonal stem-cell disorders. This may raise con­
cern about the presence of sufficient numbers of residual 
normal stem cells to perform autologous stem-cell trans-
lower DFS than ABMT for de novo AML. This difference 
was mainly due to a higher relapse rate in the MDS/sAML 
group, since the mortality rate was low in both patient 
groups. The higher relapse rate in patients treated for MDS 
or secondary leukemia suggests a higher burden of residual 
disease in these patients. For that reason, it is important to
plantation. However, chemotherapy is capable to induce a monitor carefully residual disease in future studies both by
cytogenetically normal CR in patients with a cytogenetic 
marker of the malignant clone. Seven of eight patients with 
cytogenetic abnormalities in CR after chemotherapy ap­
peared to have a cytogenetically normal bone marrow.1 In 
addition, polymerase chain reaction techniques based on X- 
chromosome inactivation patterns demonstrated polyclon- 
ality in the peripheral stem-cell harvests of three patients
cytogenetic techniques and by molecular techniques.
ABMT in first CR may be the treatment of choice for 
patients with MDS or sAML if a histocompatible sibling 
donor is lacking. Allogeneic BMT with a matched unrelated 
donor is associated with a substantially higher treatment- 
related mortality. Anderson et al26 described the results of 52 
patients with MDS and sAML transplanted with an unrelated
with MDS.23 In this retrospective analysis from the European donor. The 2-year DFS, relapse, and nonrelapse mortality
Group for Blood and Marrow Transplantation registries, only 
seven of 79 patients transplanted in first CR died due to
rates were 38%, 28%, and 48%, respectively. The incidence 
of the nonrelapse mortality was higher compared with HLA-
complications of the transplant. Moreover, the transplant- identical related recipients. Increasing age was significantly
related mortality was not higher than the transplant-related 
mortality of the matched control group of patients trans­
planted for de novo AML in first CR. This would suggest 
that the engraftment capabilities of stem cells derived from 
patients with MDS are usually sufficient to restore hemato- 
poiesis to levels that prevent fatal infectious and hemorrhagic 
complications. The administration of a higher number of 
stem cells, obtained by mobilization of the stem cells into 
the peripheral blood, may improve the speed of engraftment. 
Pilot studies showed the feasibility of collecting peripheral 
stem cells in patients in CR of MDS or sAML.24,25 The 
engraftment appeared to be much faster, but this approach
associated with increased risk of death from nonrelapse 
causes. The nonrelapse mortality was 16% in 
younger than 20 years, 66% and in patients between 21 
and 40 years, and 53% in patients older than 40 years.26 A 
substantial number of patients may not reach the autologous 
stem-cell transplant procedure due to failure to induce remis­
sion or failure to collect sufficient number of stem cells. 
Careful clinical evaluation of the prognostic factors, such as 
age, chance to achieve CR, and availability of a matched 
unrelated donor, should guide the treating physician in advis­
ing the patient of the available treatment options. Further 
analyses and prospective studies may identify patients with
is not likely to improve substantially the treatment-related MDS who will benefit from intensive antileukemic therapy
mortality of autologous transplantation in MDS, since the 
mortality is already less than 10% after the use of autologous 
bone marrow stem cells.
The main reason for treatment failure was a high relapse 
risk after the autologous stem-cell procedure. The relapse 
risk was higher than 55% for all stages and all disease cate­
gories. Late relapses beyond 2 years were rare events, al­
though only 15 patients were at risk beyond this time. Age 
less than 40 years at the time of transplant was associated 
with a significantly better prognosis, with a DFS of 39%,
followed by autologous stem-cell transplantation.
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